4 - Greenwich LifeSciences, Inc. (0001799788) (Issuer)

4 - Greenwich LifeSciences, Inc. (0001799788) (Issuer)

4 - Greenwich LifeSciences, Inc. (0001799788) (Issuer)

4 - Greenwich LifeSciences, Inc. (0001799788) (Issuer)

4 - Greenwich LifeSciences, Inc. (0001799788) (Issuer)

4 - Greenwich LifeSciences, Inc. (0001799788) (Issuer)

4 - Greenwich LifeSciences, Inc. (0001799788) (Issuer)

4 - Greenwich LifeSciences, Inc. (0001799788) (Issuer)

4 - Greenwich LifeSciences, Inc. (0001799788) (Issuer)

4 - Greenwich LifeSciences, Inc. (0001799788) (Issuer)

HC Wainwright & Co. initiated coverage of Greenwich LifeSciences with a rating of Buy and set a new price target of $78.00

Aegis Capital initiated coverage of Greenwich LifeSciences with a rating of Buy and set a new price target of $75.00

Aegis Capital initiated coverage of Greenwich LifeSciences with a rating of Buy and set a new price target of $75.00

10-Q - Greenwich LifeSciences, Inc. (0001799788) (Filer)

DEFA14A - Greenwich LifeSciences, Inc. (0001799788) (Filer)

DEF 14A - Greenwich LifeSciences, Inc. (0001799788) (Filer)

EFFECT - Greenwich LifeSciences, Inc. (0001799788) (Filer)

10-Q - Greenwich LifeSciences, Inc. (0001799788) (Filer)

D - Greenwich LifeSciences, Inc. (0001799788) (Filer)

8-K - Greenwich LifeSciences, Inc. (0001799788) (Filer)

10-Q - Greenwich LifeSciences, Inc. (0001799788) (Filer)

NT 10-Q - Greenwich LifeSciences, Inc. (0001799788) (Filer)

10-K - Greenwich LifeSciences, Inc. (0001799788) (Filer)

SC 13G - Greenwich LifeSciences, Inc. (0001799788) (Subject)

STAFFORD, Texas, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today provided the following update on corporate events. The Company's 2024 events to date are listed below: Feb 29 - Mar 1, 2024 – GBG Annual Scientific Meeting (German clinical network conference)Jun 1 - 4, 2024 – American Society of Clinical Oncology (ASCO) Annual MeetingJun 3 - 6, 2024 – BIO International Convention (partnering conference)Jun 4 - 6, 2024 – Jefferies Global Healthcare Confer

STAFFORD, Texas, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the following update of the expansion of clinical sites into Spain. As previously announced, the Company has partnered with GEICAM, the largest academic breast cancer research network in Spain, where 38 hospitals have agreed to participate in FLAMINGO-01. To date, approximately 30 out of 38 sites have conducted site initiation visits (SIVs). An SIV is followed by site activation, HLA

STAFFORD, Texas, June 26, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that it is set to join the Russell 2000 and Russell 3000 Indexes at the conclusion of the Russell indexes annual reconstitution, effective after the US markets open on July 1, 2024, according to a list of additions updated as of June 21, 2024. CEO Snehal Patel commented, "The addition of our company to the Russell 2000 Index may further increase our institutional ownership as it did in

STAFFORD, Texas, June 14, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company" or "Greenwich"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that it has entered into a securities purchase agreement with its Chief Executive Officer, Snehal Patel, for the purchase and sale of 174,825 shares of its common stock at a purchase price of $14.30 per share in a private placement. The closing of the private placement is expected to occur on or about June 18, 2024, subject to the satisfaction of customary closing conditi

STAFFORD, Texas, March 13, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that its Board of Directors has extended the lock-up of the shares owned by the Company's directors, officers, and existing pre-IPO investors to June 30, 2025 which is approximately 57 months from date of the Company's IPO. During this period, current officers, directors and certain shareholders will not be able to sell their shares of the Company's common stock unless otherwise modifi

STAFFORD, Texas, March 12, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the initiation of the first clinical sites in Europe in collaboration with GEICAM in Spain. The Company has partnered with GEICAM, the largest academic breast cancer research network in Spain, where 38 hospitals have agreed to participate in FLAMINGO-01. These sites were recently approved by Spanish authorities, which led to site initiation visits and training of the first sites t

STAFFORD, Texas, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided the following update on the expansion of the clinical trial into Europe. The Company's application to expand Flamingo-01 into Europe has been formally approved by Spain, France, Germany, Italy, and Poland. The academic networks participating in each country are Geicam (Spain), Unicancer (France), GBG (Germany), GIM (Italy), and a network of Polish sites. With this final approval, regula

STAFFORD, Texas, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today provided the following update on the expansion of the clinical trial into Europe. The Company's application to expand Flamingo-01 into Europe has been reviewed by European Medicines Agency (EMA) through EMA's Clinical Trials Information System (CTIS). The Company was informed that the manufacturing, non-clinical, clinical, statistical, and regula

STAFFORD, Texas, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today provided the following update on the Phase III clinical trial, Flamingo-01. Data Safety Monitoring Board (DSMB) The Flamingo-01 DSMB met twice in 2023 and recommended to continue the study as is without modification. No serious adverse events related to GLSI-100 have been reported to date. US Clinical Sites Participating in Flamingo-01 Approximately 30 clinical sites w

STAFFORD, Texas, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced that its Board of Directors has extended the lock-up of the shares owned by the Company's directors, officers, and existing pre-IPO investors to December 31, 2024 which is approximately 51 months from date of the Company's IPO. During this period, current officers, directors and certain shareholders will not be able to sell their shares of the Company's common stock unless otherwi

Although U.S. stocks closed lower on Thursday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company’s prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision. Below is a look at a few recent notable insider purchases. For more, check out Benzinga’s insider transactions platform. United Security Bancshares The Trade: United Security Bancshares (NASDAQ:UBFO) Director Jagroop Gill acquired a total of 14

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that it is set to join the Russell 2000 and Russell 3000 Indexes at the conclusion of the Russell indexes annual reconstitution, effective after the US markets open on July 1, 2024, according to a list of additions updated as of June 21, 2024.   CEO Snehal Patel commented, "The addition of our company to the Russell 2000 Index may further increase our institutional ownership as it did in 2021 and is a reflection of the progress we have m

The company announced that it has entered into a securities purchase agreement with its Chief Executive Officer, Snehal Patel, for the purchase and sale of 174,825 shares of its common stock at a purchase price of $14.30 per share in a private placement. The closing of the private placement is expected to occur on or about June 18, 2024, subject to the satisfaction of customary closing conditions.   The gross proceeds to the Company from the offering are expected to be approximately $2.5 million, before deducting offering expenses payable by the Company. Greenwich intends to use the net proceeds from the offering for clinical development and working capital. No investment banking fees are b

HC Wainwright & Co. analyst Yi Chen reiterates Greenwich LifeSciences (NASDAQ:GLSI) with a Buy and maintains $36 price target.

Gainers Nuwellis (NASDAQ:NUWE) stock rose 46.8% to $0.48 during Monday's after-market session. The company's market cap stands at $3.2 million. Sensei Biotherapeutics (NASDAQ:SNSE) stock rose 7.42% to $1.0. The market value of their outstanding shares is at $25.0 million. Cognition Therapeutics (NASDAQ:CGTX) stock increased by 6.98% to $1.99. The company's market cap stands at $77.6 million. Allarity Therapeutics (NASDAQ:ALLR) shares increased by 5.63% to $1.5. The company's market cap stands at $2.9 million. Purple Biotech (NASDAQ:PPBT) shares moved upwards by 4.98% to $0.48. The company's market cap stands at $12.3 million. Mereo BioPharma Group (NASDAQ:MREO) stock moved upwards by 4

Although U.S. stocks closed mostly lower on Friday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision. Below is a look at a few recent notable insider purchases. For more, check out Benzinga's insider transactions platform. Harrow The Trade: Harrow, Inc. (NASDAQ:HROW) 10% owner Opaleye Management Inc. acquired a total of 50,600 shares an ave

HC Wainwright & Co. analyst Yi Chen reiterates Greenwich LifeSciences (NASDAQ:GLSI) with a Buy and maintains $36 price target.

The Company's application to expand Flamingo-01 into Europe has been formally approved by Spain, France, Germany, Italy, and Poland. Site initiation visits have been scheduled as early as the week of March 4, 2024.

The Company was informed that the manufacturing, non-clinical, clinical, statistical, and regulatory sections of its application are acceptable and the regulators' requests for information have been addressed. The regulators have thus approved the clinical trial, marking a major milestone for the Company. The 5 individual countries in Europe will now make a final determination, and if acceptable, they will allow the first group of approximately 105 sites in Europe to begin initiation and activation. Once an individual site has been activated patients can be screened and enrolled.

HC Wainwright & Co. has decided to maintain its Buy rating of Greenwich LifeSciences (NASDAQ:GLSI) and lower its price target from $38.00 to $36.00. Shares of Greenwich LifeSciences are trading up 4.98% over the last 24 hours, at $11.80 per share. A move to $36.00 would account for a 205.08% increase from the current share price. About Greenwich LifeSciences Greenwich LifeSciences Inc is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. Its Product Candidates include; GP2, a HER2/neu transmembrane peptide that elicits a targeted immune response against HER2/neu